Invesco Reaches New 52-Week High (IVZ)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Invesco (NYSE: IVZ) hit a new 52-week high Tuesday as it is currently trading at $31.45, above its previous 52-week high of $30.25 with 1.1 million shares traded as of 9:35 a.m. ET. Average volume has been four million shares over the past 30 days.

Invesco has a market cap of $13.19 billion and is part of the financial sector and financial services industry. Shares are up 13.3% year to date as of the close of trading on Monday.

Invesco Ltd. is a publicly owned investment manager. The firm primarily provides its services to individuals, typically high net worth individuals. It also manages accounts for institutions. The firm manages separate client focused equity, fixed income, balanced portfolios. The company has a P/E ratio of 19.9, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Invesco as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Invesco Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.

null

More from Markets

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Steel and Aluminum Stocks Suffer Amidst Trade War Woes

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target